Fetal growth and risk assessment: is there an impasse? POINT by Ganzevoort, W et al.
Accepted Manuscript
Fetal growth and risk assessment: is there an impasse? POINT
Wessel Ganzevoort, Baskaran Thilaganathan, Ahmet Baschat, Sanne Gordijn
PII: S0002-9378(18)30876-7
DOI: https://doi.org/10.1016/j.ajog.2018.10.007
Reference: YMOB 12371
To appear in: American Journal of Obstetrics and Gynecology
Received Date: 2 October 2018
Accepted Date: 2 October 2018
Please cite this article as: Ganzevoort W, Thilaganathan B, Baschat A, Gordijn S, Fetal growth and risk
assessment: is there an impasse? POINT, American Journal of Obstetrics and Gynecology (2018), doi:
https://doi.org/10.1016/j.ajog.2018.10.007.
This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to
our customers we are providing this early version of the manuscript. The manuscript will undergo
copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please
note that during the production process errors may be discovered which could affect the content, and all
legal disclaimers that apply to the journal pertain.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
Fetal growth and risk assessment: is there an impasse? 
 
The Issue 
Fetal growth restriction is an indicator of placental insufficiency and is strongly associated with 
adverse perinatal outcome. There is a point that the recent dominance in the medical literature 
about which reference charts to use and dichotomization of fetal size at the 10th percentile overlooks 
the fact there is not a single cut-off in any growth chart that acts as an absolute divider between high 
and low risk for adverse outcome. Thus, the collective goal of all researchers to identify, monitor and 
effectively manage growth-restricted fetuses is better served by replacing dichotomisation of normal 
versus abnormal fetal growth at the 10th percentile by interpretation of fetal size in context with 
other known parameters of fetal risk - all as continuous parameters. The use of prospective 
comprehensive datasets should facilitate better risk assessment for the individual fetus, to help 
direct effective and appropriate interventions. The counter argument is that the debate about which 
growth standard to use was necessary and has been settled through evidence that size, and therefore 
growth, need customized limits to allow adjustment for constitutional variation, and to help 
distinguish between normal and abnormal growth. Implementation of a more precise standard has 
led to better detection of fetuses that are at risk due to growth restriction, improved application of 
additional investigations, enhanced clinical confidence in management including timely delivery, and 
ultimately increased prevention of adverse outcomes. 
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INTRODUCTION 
 
In the February 2018 issue of the AJOG, important papers were published summarising some of the 
major issues in Fetal Growth Restriction (FGR).(1) Although all researchers undoubtedly share the 
same overall goal - to improve prevention, detection and outcomes of FGR, we think the issue of 
which reference chart should be used is predominant. We argue that this impasse distracts from the 
actual issue and wastes both clinical and academic resources. In this paper we highlight how the 
focus on fetal size as a proxy for fetal growth and adequate placental nutrition has been 
oversimplified as ‘above’ or ‘below’ the 10th percentile to distinguish between apparently normal 
and abnormal fetal growth. This dichotomization results in erroneous under diagnosis of growth-
restricted fetuses among those that are apparently normally grown with the risk of adverse 
outcomes due to lack of medical attention. Conversely, among constitutionally small fetuses it leads 
to over diagnosis of FGR and risk from unnecessary obstetric intervention. FGR can result from any 
pathology affecting placental function and is associated with significant adverse short and long-
term outcomes.(2-4) Accordingly, adequate detection and risk stratification is of paramount 
importance to guide perinatal care. With over 10,000 citations on “prenatal diagnosis” or 
“definition” of FGR in current medical literature we have achieved little progress beyond the initial 
landmark observation that fetal size is apparently optimally expressed by ascribing a percentile to 
its estimate.(5) This paper argues that we should progress beyond fetal size assessment alone and 
undertake a more comprehensive risk assessment using contemporary techniques.  
 
 
WHICH FETAL GROWTH CHART? 
Population-based reference charts 
Population-based fetal size charts are created from retrospective datasets and by nature are 
descriptive – show how the fetuses in the observed population have grown. These references are 
skewed at the extremes of gestation where pathological conditions such as preeclampsia and 
preterm birth are concentrated, because these abnormal pregnancies are usually not excluded in 
their development.(5, 6) This still holds true for more recent descriptive reference charts.(7)  
 
Customised fetal growth assessment 
To overcome some of the methodological drawbacks of population-based growth charts, Gardosi et 
al. constructed growth charts that attempt to mathematically predict normal variation in growth at 
term.(8) This group introduced the idea of customisation: correcting for maternal characteristics 
that individualize the expected growth potential of the foetus.(9) Many variables have been used for 
correction such as fetal gender, maternal height, weight, ethnicity and parity. At first glance, 
ethnicity seems an intuitive variable for customisation, but ethnicity is often associated with poorer 
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socio-economic status which may be the determinant for adverse perinatal outcomes.(10) 
Definition and self-reported categorisation of race is difficult, particularly in a multi-ethnic and 
continuously mingling society.(11) Additionally, it is unknown how much can change in transition 
from a generation of severe deprivation to a well-nourished and healthy generation. We suggest 
that individual variables should be comprehensively assessed for their individual putative merits 
and their well-known existing relationship with adverse outcomes. In the available datasets of 
second and third generation of migrants, we can test how many generations are required for 
adverse effects to subside. Similar interactions may be observed for maternal weight and parity, but 
fetal gender and maternal height may have a stronger argument to be used in customisation.(7) 
Even though there may be an academic discussion about the concept of customisation, the initiative 
to use back-calculated growth charts from a healthy term cohort, and serially plot growth 
assessments in a systematic manner have significantly improved awareness about growth and 
identification of fetuses at risk.(9, 12, 13) 
 
Prescriptive growth standards 
To a certain extent, healthy populations across the world are expected to have similar fetal growth, 
because only one species of humans exists without large phylogenetic differences.(14) Recent 
initiatives have prospectively followed healthy uncomplicated pregnancies with sequential 
ultrasound to develop prescriptive growth standards, defining how a healthy foetus grows.(15-19) 
In the Intergrowth-21 study performed in eight different countries, measurement variation 
between countries was significantly smaller than within-population variation.(16, 20) This 
uniformity suggests that prescriptive growth charts are the gold reference standard. However, 
there is persistent significant variation in fetal growth within each population when environmental 
constraints are not adequately controlled for. Apparently, these factors have a significant adverse 
influence on fetal growth and not all fetuses grow the same.(18, 19) 
 
 
The way forward  
Obviously, these approaches are conceptually different, and protagonists of either approach are in 
fundamental disagreement. Much effort is put into comparing how either approach performs 
retrospectively in large datasets.(21) These analyses have inherent methodological flaws. We 
postulate that if the strength of each approach is openly and academically appreciated we may 
come to a combined approach using prescriptive charts that use clinically validated using effective 
customisation. We propose a combined approach merging datasets on an individual level to test if 
variables included in customisation or the concept of conditional centiles may be used to determine 
optimal growth for the individual.(22) Next, the relationship between these variables nd adverse 
outcomes can and must be explored - although this will remain problematic in retrospective 
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datasets because of treatment paradox. Currently, many retrospective studies compare different 
strategies in their diagnostic capacity to identify small infants at birth or those with adverse 
outcomes. These comparisons are methodologically flawed because they analyse retrospectively if 
these strategies accurately predict birth weight category or adverse outcomes, whilst ignoring the 
effects of treatment paradox. Moreover, these comparisons also overlook the issue of the balance of 
detection rates and false-positive rates - prospective and randomised trials are lacking.(23) We 
propose that the combination of the two approaches will help achieve the penultimate goal to 
define normal individual fetal growth patterns. But we should not stop there... 
 
WHAT WE ARE MISSING 
 
How relevant is fetal size? 
Size is a consequence of preceding fetal growth - reflecting fetal nutrition.  Current practice 
dichotomises normal and abnormal fetal growth at the 10th percentile. But we need to move beyond 
‘good’ or ‘bad’ fetal size. As for most continuous measures in human physiology, this is an 
oversimplification with significant sources of error. Firstly, most fetuses identified as small for 
gestational age (SGA) are constitutionally small and healthy. Secondly, many fetuses who have 
impaired growth and placental dysfunction are of apparent normal weight (schematically depicted 
in Figure 1).(24) Thirdly, fetal size only reflects nutrient transfer function of the placenta and points 
to the magnitude of placental dysfunction only by association.(25) Stillbirth risk decreases with 
higher birth weight percentiles, and the majority of fetuses born below the 3rd centile is known to 
have been exposed to significant intrauterine hypoxemia. However, there is no percentile above 
which this risk is excluded (Figure 2).(24) This is further complicated by the poor performance of 
ultrasound-based fetal growth assessment that detects only up to 50% of babies born weighing less 
than the 10th centile.(26) For the above reasons, fetal size would be better utilised as a continuous 
variable in risk calculation. 
 
Clinical outcomes of relevance 
The objective of obstetric care is not to diagnose fetal malnutrition, but to prevent the negative 
effects of placental dysfunction including fetal hypoxemia, brain damage and stillbirth. In postnatal 
life, protracted nutritional deprivation results in Kwashiorkor or Marasmus many weeks or months 
before infant demise. In contrast, an infant only survives a very short period with respiratory 
failure. The placenta is uniquely responsible for many critical body functions – namely nutrition and 
respiration. To date, clinicians have used fetal size/nutrition as a proxy for placental respiratory 
failure and risk of stillbirth, in order to avert this risk by timely delivery.(27) Many studies evaluate 
diagnostic tools or interventions by their ability to identify or prevent small babies. The outcomes 
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of relevance however, should be the variables that indicate fetal hypoxemia, such as stillbirth, the 
inability to withstand uterine contractions, and long-term neurodevelopmental outcomes. 
 
A comprehensive approach 
Focusing on fetal size parameters in isolation to detect compromise is a grossly oversimplified 
diagnostic approach and as such flawed.(28) Placental function is reflected across a number of 
variables associated with adverse outcomes that can be prenatally examined.(25) These include 
Doppler ultrasound of the fetal umbilical, middle cerebral and maternal uterine arteries, serum 
biomarkers and growth trajectory.{Gaccioli}{sovio} A recent international expert consensus 
recognised that parameters that indicate placental respiratory function should be included in the 
assessment.(29, 30) Currently, these risk factors are used in a categorical fashion, where they have 
a dose-dependent relationship with poor fetal growth and stillbirth. Risk factors and assessment 
variables are interdependent – a fact that is often disregarded in risk assessment tools 
recommended by national institutions. Finally, stillbirth is a time-dependent outcome rather than 
an overt disease – as such, it is extremely susceptible to the competing risk and intervention bias of 
elective delivery.   
 
It is now possible to use contemporary software tools to generate competing algorithms to 
undertake comprehensive risk assessment. We propose the development of a predictive approach 
that takes into account relevant variables in a continuous, non-dichotomous manner. Large datasets 
with longitudinal prospective data are currently generated from on-going clinical intervention 
trials. We need aggregate individual data from these datasets to allow prediction modelling 
followed by internal and external validation. Within these algorithms, institutions will be able to 
choose either type of growth chart (prescriptive or customised) depending on local, regional or 
national interpretation. Once individual risk assessment is available, the rational next step is to feed 
intervention trials.  
 
CONCLUSION 
Currently, one issue dominates much of the debate amongst valued individual researchers - which 
growth chart to use to assess normal or abnormal fetal size? We argue that we need to abandon that 
gridlock because it obscures the bigger and more clinically relevant picture. The current standstill 
effectively prohibits progress towards the sketched horizon with a comprehensive risk assessment 
that will benefit the prenatal care for patients.  
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FIGURE LEGEND 
 
Figure 1. Schematic depiction of the overlap and difference between FGR and SGA. 
FGR = Fetal Growth Restriction; SGA = Small for Gestational Age; AGA = Appropriate for Gestational 
Age; LGA = Large for Gestational Age;  
x-axis represents growth percentile, y-axis represents percentage of the population; red area 
represents fetuses with FGR; 
 
 
 
Figure 2. Examples of linear relationship between birth weight percentile and clinical outcomes. 
A. Percentage of 11.576 term fetuses with failure to reach growth potential (FRGP) according to their 
birth weight (BW) centile group (i.e. percentage of fetuses presenting an abnormal cerebroplacental 
ratio (CPR) calculated after subtracting those cases with abnormal CPR in the group with BW > 90th 
centile).(31)  
B. Perinatal mortality according to birth weight centiles in Dutch Perinatal Registry in all 
(n=1.170.534) cases 28-43 weeks excluding congenital anomalies.(24) 
C. Absolute risk per 10,000 pregnancies of term stillbirth by birth weight percentile among 784,576 
singleton births in Scottish registries.(32) 
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